These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7992071)

  • 1. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy.
    Greco FA; Hainsworth JD
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):77-82. PubMed ID: 7992071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):116-22. PubMed ID: 2669133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site.
    Hainsworth JD; Greco FA
    Semin Oncol; 1993 Jun; 20(3):279-86. PubMed ID: 8503024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoma of unknown primary site.
    Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
    Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poorly differentiated carcinoma and germ cell tumors.
    Hainsworth JD; Greco FA
    Hematol Oncol Clin North Am; 1991 Dec; 5(6):1223-31. PubMed ID: 1663941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
    Hainsworth JD; Johnson DH; Greco FA
    J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
    Greco FA; Johnson DH; Hainsworth JD
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing carcinomas of unknown primary site.
    Hainsworth JD; Greco FA
    Oncology (Williston Park); 1988 Jul; 2(7):43-9, 52-4. PubMed ID: 3275052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Dial TW; Greco FA
    Am J Clin Oncol; 1988 Apr; 11(2):138-45. PubMed ID: 2451881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Johnson DH; Greco FA
    Semin Oncol; 1992 Apr; 19(2 Suppl 5):54-7; discussion 58. PubMed ID: 1384145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site.
    Park YH; Ryoo BY; Choi SJ; Yang SH; Kim HT
    Jpn J Clin Oncol; 2004 Nov; 34(11):681-5. PubMed ID: 15613558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiac metastasis of poorly differentiated adenocarcinoma of unknown primary site].
    Mazzoccoli G; Carughi S; La Viola M; De Cata A; Puzzolante F; Camagna A; Russo A; Caparrotti S
    Ital Heart J Suppl; 2002 Nov; 3(11):1112-6. PubMed ID: 12506513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytostatic treatment of metastatic adenocarcinoma and anaplastic carcinoma of unknown primary origin].
    Aabo K; Rørth M; Hansen HH
    Ugeskr Laeger; 1987 Jan; 149(2):80-1. PubMed ID: 3810973
    [No Abstract]   [Full Text] [Related]  

  • 16. Multiple nodules on the face and trunk in metastatic adenocarcinoma of unknown primary origin.
    Furtado S; Bhat RM; Sukumar D; Krishnamurthy SG; Rao SD; Nandakishore B
    Singapore Med J; 2011 Jul; 52(7):e163-6. PubMed ID: 21808952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
    Kato S; Yasuda K; Nishino Y; Ohori H; Takahashi M; Takahashi S; Yamaura G; Ohtsuka K; Kakudo Y; Chiba N; Shimodaira H; Sakayori M; Kato S; Suzuki T; Murakawa Y; Gamoh M; Shibata H; Yoshioka T; Ishioka C
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1227-31. PubMed ID: 17687203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.
    Hejna M; Kornek GV; Schratter-Sehn AU; Zach M; Schoder M; Raderer M; Rosen H; Schiessel R; Scheithauer W
    Cancer; 1996 Oct; 78(8):1646-50. PubMed ID: 8859175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving role of paclitaxel for patients with carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):129-33. PubMed ID: 10190795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine carcinoma of unknown primary site.
    Spigel DR; Hainsworth JD; Greco FA
    Semin Oncol; 2009 Feb; 36(1):52-9. PubMed ID: 19179188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.